News Feed Item

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

NEW YORK, Jan. 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022


The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Treatment options in China are extremely limited compared with the 7MM. Although some recombinant replacement therapies for hemophilia A and B, such as Recombinate, Xyntha, Kogenate, Advate and BeneFIX, are approved for marketing in China, they are not covered by national or provisional insurance programs and access to these drugs is extremely limited.


- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis and Quality of Life 16

3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
4.2 China 24
4.2.1 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitive Assessment 27
5.3 Product Profiles - Major Brands, Hemophilia A 31
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 31
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 35
5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 38
5.4 Product Profiles - Hemophilia B 40
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 40
5.4.2 Rixubis (BAX-326) 43
5.5 Product Profiles - Hemophilia A and B with Inhibitors 46
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 46

6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 Opportunities Analysis 49
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 49
6.2.2 Lower-Cost Recombinant Replacement Therapies 50
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 51
6.2.4 More Convenient Drug Administration 51
6.2.5 Oral Formulation of Recombinant Replacement Therapies 52
6.3 Unmet Needs Gap Analysis 52
6.3.1 Long-Acting FVIII Replacement Therapies 52
6.3.2 Gene Therapy Treatments for Hemophilia A and B 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Promising Drugs in Clinical Development - Hemophilia A 54
7.2.1 BAY 94-9027 (octocog alfa) 56
7.2.2 BAX-855 59
7.2.3 Novoeight (turoctocog alfa; NN7008) 63
7.2.4 N8-GP (NN7088) 66
8 Market Outlook 70
8.1 China 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 73
9 Appendix 75
9.1 Bibliography 75
9.2 Abbreviations 83

9.3 Methodology 86
9.4 Forecasting Methodology 86
9.4.1 Diagnosed Hemophilia Patients 87
9.4.2 Percent Drug-Treated Patients 87
9.4.3 Drugs Included in Each Therapeutic Class 88
9.4.4 Launch and Patent Expiry Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Drug Assumptions 89
9.4.7 Pricing of Pipeline Agents 92
9.5 Physicians and Specialists Included in this Study 93
9.6 About the Authors 95
9.6.1 Authors 95
9.6.2 Global Head of Healthcare 96
9.7 About GlobalData 97
9.8 Disclaimer 97

1.1 List of Tables

Table 1: Symptoms of Hemophilia A and B 18
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 23
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 29
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 30
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 32
Table 6: Advate SWOT Analysis, 2013 34
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 36
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 38
Table 9: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 39

Table 10: Recombinate SWOT Analysis, 2013 40
Table 11: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 41
Table 12: BeneFIX SWOT Analysis, 2013 42
Table 13: Product Profile - Rixubis (BAX-326) 44
Table 14: Rixubis SWOT Analysis, 2013 45
Table 15: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 46
Table 16: NovoSeven RT SWOT Analysis, 2013 47
Table 17: Overall Unmet Needs - Current Level of Attainment 49
Table 18: Hemophilia A - Phase I/II Pipeline, 2013 54
Table 19: Hemophilia A - Phase III Pipeline, 2013 55
Table 20: Product Profile - BAY 94-9027 56
Table 21: BAY 94-9027 SWOT Analysis, 2013 59
Table 22: Product Profile - BAX-855 60
Table 23: BAX-855 SWOT Analysis, 2013 62
Table 24: Product Profile - Novoeight (turoctocog alfa; NN7008) 63
Table 25: Novoeight SWOT Analysis, 2013 66
Table 26: Product Profile - N8-GP (NN7088) 67
Table 27: N8-GP SWOT Analysis, 2013 69
Table 28: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 71
Table 29: Key Events Impacting Sales for Hemophilia A and B in China, 2013 73
Table 30: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 73
Table 31: Product Launch Dates 88
Table 32: Physicians Surveyed 93

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 55
Figure 2: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 72

To order this report: PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Internet of Things (IoT), in all its myriad manifestations, has great potential. Much of that potential comes from the evolving data management and analytic (DMA) technologies and processes that allow us to gain insight from all of the IoT data that can be generated and gathered. This potential may never be met as those data sets are tied to specific industry verticals and single markets, with no clear way to use IoT data and sensor analytics to fulfill the hype being given the IoT today.
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...